Aripiprazole is an atypical antipsychotic drug that is mainly transformed by the hepatic enzymes CYP2D6 and CYP3A4. Dose adjustment is recommended for CYP2D6-poor metabolizers. Aripiprazole is generally well tolerated by most adult patients, but occasionally adverse effects can occur in some individuals resulting in the drug being withdrawn. Recent studies suggested that other genes involved in drug metabolism, transport, and elimination can be related to the efficacy and safety of drug therapy. This study aimed to evaluate the differences in genetic variants between patients who tolerated the therapy well and those who experienced adverse effects leading to withdrawing the drug. The genetic profiling of 20 genes was performed using MassARRAY technology. No differences between both groups in the ABCB1, COMT, CYP2D6, CYP3A4, and CYP3A5 polymorphisms were found. Unexpectedly, we observed a higher frequency of homozygous CYP1A21F/*1F (78% vs. 45%) and CYP2B6*1/*1 (80% vs. 45%) as well as the frequency of CYP1A2 ultra-rapid metabolizes in the group with adverse effects. Moreover, a combined homozygous status (CYP1A2*1F/*1F/ CYP2B6*1/*1) has been exclusively identified in patients with adverse effects. To date, there are no findings about the possible role of CYP1A2 and CYP2B6 enzymes in aripiprazole metabolism. Thus, our preliminary data suggest that the CYP1A2*F and/or CYP2B6*1 alleles may contribute to the adverse effects of aripiprazole. Therefore, further studies on larger sample sizes are needed to confirm our findings.
1. Vasiliu O. Third-generation antipsychotics in patients with schizophrenia and non-responsivity or intolerance to clozapine regimen: What is the evidence? Front Psychiatry. 2022;13:1069432. doi:10.3389/fpsyt.2022.1069432
2. Kikuchi T, Maeda K, Suzuki M, Hirose T, Futamura T, McQuade RD. Discovery research and development history of the dopamine D 2 receptor partial agonists, aripiprazole and brexpiprazole. Neuropsychopharmacol Rep. 2021;41(2):134-43. doi:10.1002/npr2.12180
3. Koller D, Abad-Santos F. The pharmacogenetics of aripiprazole-induced hyperprolactinemia: what do we know? Pharmacogenomics. 2020;21(9):571-4.
4. Dean L, Kane M. Aripiprazole therapy and CYP2D6 genotype. 2021 2021/02/10. National Center for Biotechnology Information (US). Available from: https://www.ncbi.nlm.nih.gov/pubmed/.
5. Belmonte C, Ochoa D, Román M, Saiz‐Rodríguez M, Wojnicz A, Gómez‐Sánchez CI, et al. Influence of CYP 2D6, CYP 3A4, CYP 3A5 and ABCB 1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers. Basic Clin Pharmacol Toxicol. 2018;122(6):596-605.
6. Milosavljević F, Bukvić N, Pavlović Z, Miljević Č, Pešić V, Molden E, et al. Association of CYP2C19 and CYP2D6 poor and intermediate metabolizer status with antidepressant and antipsychotic exposure: a systematic review and meta-analysis. JAMA Psychiatry. 2021;78(3):270-80.
7. Prommer E. Aripiprazole. Am J Hosp Palliat Care. 2017;34(2):180-5.
8. Findling RL, Robb A, Nyilas M, Forbes RA, Jin N, Ivanova S, et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry. 2008;165(11):1432-41.
9. Kwon JS, Kim E, Kang DH, Choi JS, Yu KS, Jang IJ, et al. Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole. Eur Neuropsychopharmacol. 2008;18(12):897-907.
10. Chen SF, Shen YC, Chen CH. HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients. Psychopharmacology (Berl). 2009;205(2):285-92.
11. Koller D, Almenara S, Mejía G, Saiz-Rodríguez M, Zubiaur P, Román M, et al. Safety and cardiovascular effects of multiple-dose administration of aripiprazole and olanzapine in a randomised clinical trial. Hum Psychopharmacol. 2021;36(1):1-12.
12. Langmia IM, Just KS, Yamoune S, Brockmöller J, Masimirembwa C, Stingl JC. CYP2B6 Functional Variability in Drug Metabolism and Exposure Across Populations—Implication for Drug Safety, Dosing, and Individualized Therapy. Front Genet. 2021;12:692234. doi:10.3389/fgene.2021.692234
13. Koller D, Saiz-Rodríguez M, Zubiaur P, Ochoa D, Almenara S, Román M, et al. The effects of aripiprazole and olanzapine on pupillary light reflex and its relationship with pharmacogenetics in a randomized multiple-dose trial. Br J Clin Pharmacol. 2020;86(10):2051-62.
14. Koller D. Evaluation of genetic polymorphisms associated with the metabolic effects of aripiprazole and olanzapine. Doctoral Thesis. 2020.
15. Sanchez Spitman AB, Moes DJAR, Gelderblom H, Dezentje VO, Swen JJ, Guchelaar HJ. Effect of CYP3A422, CYP3A53, and CYP3A combined genotypes on tamoxifen metabolism. Eur J Clin Pharmacol. 2017;73(12):1589-98.
16. Vautier S, Fernandez C. ABCB1: the role in Parkinson's disease and pharmacokinetics of antiparkinsonian drugs. Expert Opin Drug Metab Toxicol. 2009;5(11):1349-58.
17. Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, Melhem S, et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet. 2004;75(5):807-21.
18. Jukic MM, Smith RL, Haslemo T, Molden E, Ingelman-Sundberg M. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study. Lancet Psychiatry. 2019;6(5):418-26. doi:10.1016/s2215-0366(19)30088-4
19. Subuh Surja AA, Reynolds KK, Linder MW, El-Mallakh RS. Pharmacogenetic testing of CYP2D6 in patients with aripiprazole-related extrapyramidal symptoms: a case-control study. Per Med. 2008;5(4):361-5.
20. Cendrós M, Arranz MJ, Torra M, Penadés R, Gonzalez-Rodriguez A, Brunet M, et al. The influence of CYP enzymes and ABCB1 on treatment outcomes in schizophrenia: association of CYP1A2 activity with adverse effects. J Transl Genet Genom. 2020;4(3):210-20.